Exploring the transcriptional cooperation between RUNX2 and its associated elncRNA RAIN.


Journal

Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092

Informations de publication

Date de publication:
14 Sep 2024
Historique:
received: 08 02 2024
accepted: 04 09 2024
revised: 30 08 2024
medline: 14 9 2024
pubmed: 14 9 2024
entrez: 13 9 2024
Statut: epublish

Résumé

Recent insights into the mechanisms controlling gene expression identified enhancer-associated long non-coding RNAs (elncRNAs) as master players of transcription in cancers. RUNX2, a mammalian RUNT-related transcription factor, is increasingly recognized in cancer biology for its role in supporting survival and progression also in thyroid cancer (TC). We recently identified, within the RUNX2 locus, a novel elncRNA that we named RAIN (RUNX2 associated intergenic lncRNA). We showed that RAIN and RUNX2 expression correlate in TC, both in vitro and in vivo, and that RAIN promotes RUNX2 expression by interacting with and affecting the activity of the RUNX2 P2 promoter through two distinct mechanisms. Here, we took forward these observations to explore the genome-wide transcriptional function of RAIN and its contribution to the RUNX2-dependent gene expression program in TC. By combining multiple omics data, we demonstrated that RAIN functionally cooperates with RUNX2 to the regulation of a subset of functionally related genes involved in promoting matrix remodeling, migration, and loss of differentiation. We showed that RAIN interacts with RUNX2 and its expression is required for the efficient recruitment of this TF to its target regulatory regions. In addition, our data revealed that besides RUNX2, RAIN governs a hierarchically organized complex transcriptional program by controlling a core of cancer-associated TFs that, in turn, orchestrate the expression of downstream genes. This evidence indicates that the functional cooperation observed between RAIN and RUNX2 can be a diffuse work mechanism for this elncRNA.

Identifiants

pubmed: 39271656
doi: 10.1038/s41419-024-07058-x
pii: 10.1038/s41419-024-07058-x
doi:

Substances chimiques

Core Binding Factor Alpha 1 Subunit 0
RNA, Long Noncoding 0
RUNX2 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

673

Subventions

Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : AIRC IG21772

Informations de copyright

© 2024. The Author(s).

Références

Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31–46.
pubmed: 35022204 doi: 10.1158/2159-8290.CD-21-1059
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
pubmed: 21376230 doi: 10.1016/j.cell.2011.02.013
Vervoort SJ, Devlin JR, Kwiatkowski N, Teng M, Gray NS, Johnstone RW. Targeting transcription cycles in cancer. Nat Rev Cancer. 2022;22:5–24.
pubmed: 34675395 doi: 10.1038/s41568-021-00411-8
Consortium EP, Moore JE, Purcaro MJ, Pratt HE, Epstein CB, Shoresh N, et al. Expanded encyclopaedias of DNA elements in the human and mouse genomes. Nature. 2020;583:699–710.
doi: 10.1038/s41586-020-2493-4
Zhang J, Lee D, Dhiman V, Jiang P, Xu J, McGillivray P, et al. An integrative ENCODE resource for cancer genomics. Nat Commun. 2020;11:3696.
pubmed: 32728046 pmcid: 7391744 doi: 10.1038/s41467-020-14743-w
Vierstra J, Lazar J, Sandstrom R, Halow J, Lee K, Bates D, et al. Global reference mapping of human transcription factor footprints. Nature. 2020;583:729–36.
pubmed: 32728250 pmcid: 7410829 doi: 10.1038/s41586-020-2528-x
Bradner JE, Hnisz D, Young RA. Transcriptional addiction in cancer. Cell. 2017;168:629–43.
pubmed: 28187285 pmcid: 5308559 doi: 10.1016/j.cell.2016.12.013
Bushweller JH. Targeting transcription factors in cancer - from undruggable to reality. Nat Rev Cancer. 2019;19:611–24.
pubmed: 31511663 pmcid: 8820243 doi: 10.1038/s41568-019-0196-7
Blyth K, Cameron ER, Neil JC. The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer. 2005;5:376–87.
pubmed: 15864279 doi: 10.1038/nrc1607
Lin TC. RUNX2 and cancer. Int J Mol Sci 2023;24:7001.
Endo T, Ohta K, Kobayashi T. Expression and function of Cbfa-1/Runx2 in thyroid papillary carcinoma cells. J Clin Endocrinol Metab. 2008;93:2409–12.
pubmed: 18381576 doi: 10.1210/jc.2007-2805
Owens TW, Rogers RL, Best S, Ledger A, Mooney AM, Ferguson A, et al. Runx2 is a novel regulator of mammary epithelial cell fate in development and breast cancer. Cancer Res. 2014;74:5277–86.
pubmed: 25056120 pmcid: 4178131 doi: 10.1158/0008-5472.CAN-14-0053
Javed A, Barnes GL, Pratap J, Antkowiak T, Gerstenfeld LC, van Wijnen AJ, et al. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci USA. 2005;102:1454–9.
pubmed: 15665096 pmcid: 547873 doi: 10.1073/pnas.0409121102
Sancisi V, Manzotti G, Gugnoni M, Rossi T, Gandolfi G, Gobbi G, et al. RUNX2 expression in thyroid and breast cancer requires the cooperation of three non-redundant enhancers under the control of BRD4 and c-JUN. Nucleic Acids Res. 2017;45:11249–67.
pubmed: 28981843 pmcid: 5737559 doi: 10.1093/nar/gkx802
Sancisi V, Gandolfi G, Ragazzi M, Nicoli D, Tamagnini I, Piana S, et al. Cadherin 6 is a new RUNX2 target in TGF-beta signalling pathway. PLoS ONE. 2013;8:e75489.
pubmed: 24069422 pmcid: 3772092 doi: 10.1371/journal.pone.0075489
Sancisi V, Gandolfi G, Ambrosetti DC, Ciarrocchi A. Histone deacetylase inhibitors repress tumoral expression of the proinvasive factor RUNX2. Cancer Res. 2015;75:1868–82.
pubmed: 25769725 doi: 10.1158/0008-5472.CAN-14-2087
Sancisi V, Borettini G, Maramotti S, Ragazzi M, Tamagnini I, Nicoli D, et al. Runx2 isoform I controls a panel of proinvasive genes driving aggressiveness of papillary thyroid carcinomas. J Clin Endocrinol Metab. 2012;97:E2006–2015.
pubmed: 22821892 pmcid: 3462932 doi: 10.1210/jc.2012-1903
Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22:96–118.
pubmed: 33353982 doi: 10.1038/s41580-020-00315-9
Ransohoff JD, Wei Y, Khavari PA. The functions and unique features of long intergenic non-coding RNA. Nat Rev Mol Cell Biol. 2018;19:143–57.
pubmed: 29138516 doi: 10.1038/nrm.2017.104
Zhou M, Bao S, Gong T, Wang Q, Sun J, Li J, et al. The transcriptional landscape and diagnostic potential of long non-coding RNAs in esophageal squamous cell carcinoma. Nat Commun. 2023;14:3799.
pubmed: 37365153 pmcid: 10293239 doi: 10.1038/s41467-023-39530-1
Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77:3965–81.
pubmed: 28701486 pmcid: 8330958 doi: 10.1158/0008-5472.CAN-16-2634
Rossi T, Pistoni M, Sancisi V, Gobbi G, Torricelli F, Donati B, et al. RAIN is a novel enhancer-associated lncRNA that controls RUNX2 expression and promotes breast and thyroid cancer. Mol Cancer Res. 2020;18:140–52.
pubmed: 31624086 doi: 10.1158/1541-7786.MCR-19-0564
Gugnoni M, Manzotti G, Vitale E, Sauta E, Torricelli F, Reggiani F, et al. OVOL2 impairs RHO GTPase signaling to restrain mitosis and aggressiveness of anaplastic thyroid cancer. J Exp Clin Cancer Res. 2022;41:108.
pubmed: 35337349 pmcid: 8957195 doi: 10.1186/s13046-022-02316-2
Chu C, Chang HY. Understanding RNA-chromatin interactions using chromatin isolation by RNA purification (ChIRP). Methods Mol Biol. 2016;1480:115–23.
pubmed: 27659979 doi: 10.1007/978-1-4939-6380-5_10
Fragliasso V, Verma A, Manzotti G, Tameni A, Bareja R, Heavican TB, et al. The novel lncRNA BlackMamba controls the neoplastic phenotype of ALK− anaplastic large cell lymphoma by regulating the DNA helicase HELLS. Leukemia. 2020;34:2964–80.
pubmed: 32123306 doi: 10.1038/s41375-020-0754-8
Sanghi A, Gruber JJ, Metwally A, Jiang L, Reynolds W, Sunwoo J, et al. Chromatin accessibility associates with protein-RNA correlation in human cancer. Nat Commun. 2021;12:5732.
pubmed: 34593797 pmcid: 8484618 doi: 10.1038/s41467-021-25872-1
Andrews S. FASTQC. A quality control tool for high throughput sequence data. 2010. www.bioinformatics.babraham.ac.uk/projects/fastqc/ .
Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinforma. 2011;12:323.
doi: 10.1186/1471-2105-12-323
Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21.
pubmed: 23104886 doi: 10.1093/bioinformatics/bts635
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.
pubmed: 25516281 pmcid: 4302049 doi: 10.1186/s13059-014-0550-8
Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30:2114–20.
pubmed: 24695404 pmcid: 4103590 doi: 10.1093/bioinformatics/btu170
Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9:357–9.
pubmed: 22388286 pmcid: 3322381 doi: 10.1038/nmeth.1923
Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, et al. Twelve years of SAMtools and BCFtools. GigaScience. 2021;10:giab008.
Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al. Model-based analysis of ChIP-seq (MACS). Genome Biol. 2008;9:R137.
pubmed: 18798982 pmcid: 2592715 doi: 10.1186/gb-2008-9-9-r137
Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26:841–2.
pubmed: 20110278 pmcid: 2832824 doi: 10.1093/bioinformatics/btq033
Yu G, Wang L-G, He Q-Y. ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization. Bioinformatics. 2015;31:2382–3.
pubmed: 25765347 doi: 10.1093/bioinformatics/btv145
Grant CE, Bailey TL, Noble WS. FIMO: scanning for occurrences of a given motif. Bioinformatics. 2011;27:1017–8.
pubmed: 21330290 pmcid: 3065696 doi: 10.1093/bioinformatics/btr064
Gandolfi G, Ragazzi M, de Biase D, Visani M, Zanetti E, Torricelli F, et al. Genome-wide profiling identifies the THYT1 signature as a distinctive feature of widely metastatic Papillary Thyroid Carcinomas. Oncotarget. 2018;9:1813–25.
pubmed: 29416733 doi: 10.18632/oncotarget.22805
Gandolfi G, Ragazzi M, Frasoldati A, Piana S, Ciarrocchi A, Sancisi V. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma. Eur J Endocrinol. 2015;172:403–13.
pubmed: 25583906 doi: 10.1530/EJE-14-0837
Vitale E, Sauta E, Gugnoni M, Torricelli F, Manicardi V, Ciarrocchi A. A multimodal integrative approach to model transcriptional addiction of thyroid cancer on RUNX2. Cancer Commun. 2022;42:892–6.
doi: 10.1002/cac2.12292
Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC, et al. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science. 2001;294:2563–6.
DiFeo A, Feld L, Rodriguez E, Wang C, Beer DG, Martignetti JA, et al. A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response. Cancer Res. 2008;68:965–70.
pubmed: 18250346 pmcid: 2826216 doi: 10.1158/0008-5472.CAN-07-2604
Baena E, Shao Z, Linn DE, Glass K, Hamblen MJ, Fujiwara Y, et al. ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev. 2013;27:683–98.
pubmed: 23512661 pmcid: 3613614 doi: 10.1101/gad.211011.112
Kang M-H, Choi H, Oshima M, Cheong J-H, Kim S, Lee JH, et al. Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer. Nat Commun. 2018;9:1920.
pubmed: 29765046 pmcid: 5954140 doi: 10.1038/s41467-018-04244-2
Li L-Y, Yang Q, Jiang Y-Y, Yang W, Jiang Y, Li X, et al. Interplay and cooperation between SREBF1 and master transcription factors regulate lipid metabolism and tumor-promoting pathways in squamous cancer. Nat Commun. 2021;12:4362.
pubmed: 34272396 pmcid: 8285542 doi: 10.1038/s41467-021-24656-x
Lin T-C. RUNX1 and cancer. Biochimica et Biophysica Acta Rev Cancer. 2022;1877:188715.
doi: 10.1016/j.bbcan.2022.188715
Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, Stein JL, et al. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev. 2006;25:589–600.
pubmed: 17165130 doi: 10.1007/s10555-006-9032-0
Yin X, Teng X, Ma T, Yang T, Zhang J, Huo M, et al. RUNX2 recruits the NuRD(MTA1)/CRL4B complex to promote breast cancer progression and bone metastasis. Cell Death Differ. 2022;29:2203–17.
pubmed: 35534547 pmcid: 9613664 doi: 10.1038/s41418-022-01010-2
Chimge NO, Baniwal SK, Little GH, Chen YB, Kahn M, Tripathy D, et al. Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2. Breast Cancer Res. 2011;13:R127.
pubmed: 22151997 pmcid: 3326569 doi: 10.1186/bcr3073
Yi H, Li G, Long Y, Liang W, Cui H, Zhang B, et al. Integrative multi-omics analysis of a colon cancer cell line with heterogeneous Wnt activity revealed RUNX2 as an epigenetic regulator of EMT. Oncogene. 2020;39:5152–64.
pubmed: 32535615 doi: 10.1038/s41388-020-1351-z
Barnes GL, Javed A, Waller SM, Kamal MH, Hebert KE, Hassan MQ, et al. Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res. 2003;63:2631–7.
pubmed: 12750290
Barnes GL, Hebert KE, Kamal M, Javed A, Einhorn TA, Lian JB, et al. Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease. Cancer Res. 2004;64:4506–13.
pubmed: 15231660 doi: 10.1158/0008-5472.CAN-03-3851
Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS, et al. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol. 2005;25:8581–91.
pubmed: 16166639 pmcid: 1265732 doi: 10.1128/MCB.25.19.8581-8591.2005
Mendoza-Villanueva D, Zeef L, Shore P. Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFbeta-dependent expression of the Wnt antagonist, sclerostin. Breast Cancer Res. 2011;13:R106.
pubmed: 22032690 pmcid: 3262219 doi: 10.1186/bcr3048
Vance KW, Sansom SN, Lee S, Chalei V, Kong L, Cooper SE, et al. The long non‐coding RNA Paupar regulates the expression of both local and distal genes. EMBO J. 2014;33:296–311.
Ferrer J, Dimitrova N. Transcription regulation by long non-coding RNAs: mechanisms and disease relevance. Nat Rev Molecular Cell Biol. 2024;25:396–415.

Auteurs

Emanuele Vitale (E)

Laboratory of Translational Research, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.

Veronica Manicardi (V)

Laboratory of Translational Research, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Mila Gugnoni (M)

Laboratory of Translational Research, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Federica Torricelli (F)

Laboratory of Translational Research, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Benedetta Donati (B)

Laboratory of Translational Research, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Silvia Muccioli (S)

Laboratory of Translational Research, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Elisa Salviato (E)

Laboratory of Translational Research, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Teresa Rossi (T)

Laboratory of Translational Research, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Gloria Manzotti (G)

Laboratory of Translational Research, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Simonetta Piana (S)

Pathology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Alessia Ciarrocchi (A)

Laboratory of Translational Research, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy. Alessia.Ciarrocchi@ausl.re.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH